BiotechTube

5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Benign Prostate Hyperplasia

Conditions

Benign Prostate Hyperplasia, Erectile Dysfunction

Trial Timeline

Sep 1, 2013 → Dec 1, 2015

NCT ID
NCT01937871

About 5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin

5 mg Tadalafil + Placebo + 0.2 mg Tamsulosin is a phase 3 stage product being developed by Eli Lilly for Benign Prostate Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01937871. Target conditions include Benign Prostate Hyperplasia, Erectile Dysfunction.

What happened to similar drugs?

8 of 20 similar drugs in Benign Prostate Hyperplasia were approved

Approved (8) Terminated (3) Active (9)
🔄Tadalafil + PlaceboEli LillyPhase 3
🔄Placebo + tadalafilEli LillyPhase 3
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
🔄Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01937871Phase 3Completed

Competing Products

20 competing products in Benign Prostate Hyperplasia

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
ASP4901 + Tamsulosin + PlaceboAstellas PharmaPhase 2
35
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
39
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyPhase 1
29
Tadalafil + Placebo + TamsulosinEli LillyPhase 3
40
Tadalafil 2.5 mg + Tadalafil 5 mg + PlaceboEli LillyPhase 2
35
Tadalafil 5 mg + Placebo tablet + Tamsulosin + Placebo capsuleEli LillyPhase 3
40
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + TamsulosinEli LillyPhase 2
35
Tadalafil + PlaceboEli LillyPhase 3
40
tadalafil + tadalafil + tadalafil + tadalafil + placeboEli LillyPhase 2/3
38
Tadalafil + Placebo + FinasterideEli LillyPhase 3
40